Most-Downgraded StocksMost-DowngradedNYSE:BSX Boston Scientific (BSX) Stock Price, News & Analysis $45.42 -0.27 (-0.58%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Boston Scientific Stock (NYSE:BSX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Boston Scientific alerts:Sign Up Key Stats Today's Range$45.13▼$46.0750-Day Range$41.55▼$52.0252-Week Range$41.38▼$105.65Volume5.83 million shsAverage Volume18.41 million shsMarket Capitalization$65.83 billionP/E Ratio18.38Dividend YieldN/APrice Target$68.07Consensus RatingModerate Buy Company Overview Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide. Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation. Boston Scientific’s portfolio includes devices such as stents, catheters, cardiac rhythm management and ablation technologies, endoscopic tools, devices for treating urinary and pelvic conditions, and systems used in pain management. The company sells its products through direct sales organizations and distributors across North America, Europe, Asia-Pacific, Latin America and other international markets. Boston Scientific is led by Michael F. Mahoney, who serves as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Boston Scientific Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreBSX MarketRank™: 4.920367121065 of 5 starsBoston Scientific scored higher than 98% of companies evaluated by MarketBeat, and ranked 2nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBoston Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 1 strong buy rating, 25 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialBoston Scientific has a consensus price target of $68.07, representing about 50.7% upside from its current price of $45.16.Amount of Analyst CoverageBoston Scientific has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Boston Scientific's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3.70% Earnings GrowthEarnings for Boston Scientific are expected to grow by 3.70% in the coming year, from $3.24 to $3.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Boston Scientific is 18.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.83.Price to Earnings Ratio vs. SectorThe P/E ratio of Boston Scientific is 18.28, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.74.Price to Earnings Growth RatioBoston Scientific has a PEG Ratio of 1.10. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBoston Scientific has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Boston Scientific's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.87% of the float of Boston Scientific has been sold short.Short Interest Ratio / Days to CoverBoston Scientific has a short interest ratio ("days to cover") of 1.88, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Boston Scientific has recently decreased by 10.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBoston Scientific does not currently pay a dividend.Dividend GrowthBoston Scientific does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.90 News SentimentBoston Scientific has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Boston Scientific this week, compared to 7 articles on an average week.Search InterestOnly 61 people have searched for BSX on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat Follows16 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Boston Scientific in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $9,385,210.00 in company stock, which represents 0.0143% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Boston Scientific insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,385,210.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.34% of the stock of Boston Scientific is held by insiders.Percentage Held by Institutions89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Boston Scientific's insider trading history. Receive BSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BSX Stock News HeadlinesBoston Scientific to participate in Stifel's 2026 Healthcare ConferenceOctober 26 at 8:00 AM | prnewswire.comBoston Scientific Corporation (NYSE:BSX) Stock Has Consensus Price Target of $68.23October 25 at 2:29 AM | americanbankingnews.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.October 26 at 1:00 AM | American Alternative (Ad)Boston Scientific: A Q3 Earnings Miss Likely Amid Product Recall, Cybersecurity IncidentOctober 22, 2026 | seekingalpha.comBoston Scientific: A Q3 Earnings Miss Likely Amid Product Recall, Cybersecurity IncidentOctober 22, 2026 | seekingalpha.comCan Boston Scientific Stock Bounce Off This Support Again?October 21, 2026 | finance.yahoo.comBoston Scientific (BSX) Set to Post Earnings on WednesdayOctober 21, 2026 | americanbankingnews.comBoston Scientific: A Better Valuation, But The Turnaround Needs ProofOctober 16, 2026 | seekingalpha.comSee More Headlines BSX Stock Analysis - Frequently Asked Questions How have BSX shares performed this year? Boston Scientific's stock was trading at $95.29 at the beginning of 2026. Since then, BSX stock has decreased by 52.6% and is now trading at $45.1640. How were Boston Scientific's earnings last quarter? Boston Scientific Corporation (NYSE:BSX) announced its quarterly earnings results on Wednesday, July, 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. Boston Scientific's revenue was up 7.5% compared to the same quarter last year. Read the conference call transcript. Is Boston Scientific buying back stock? Boston Scientific's Board of Directors authorized a stock buyback program on Monday, May 18th 2026, which authorizes the company to buy back $5 billion in shares, according to EventVestor. This means that the company could purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's management believes its shares are undervalued. Does Boston Scientific have any subsidiaries? The following companies are subsidiaries of Boston Scientific: VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and others. Who are Boston Scientific's major shareholders? Boston Scientific's top institutional investors include Assenagon Asset Management S.A. (0.47%), ZWJ Investment Counsel Inc. (0.05%), Mn Services Vermogensbeheer B.V. (0.03%) and Gradient Investments LLC (0.03%). Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Vance R Brown, Eric Francis Yves Thepaut, Edward J Ludwig, Edward J Ludwig, Wendy Carruthers, Jeffrey B Mirviss, Ellen M Zane, Arthur C Butcher, John Bradley Sorenson, David C Habiger, Yoshiaki Fujimori, Cheryl Pegus and Charles J Dockendorff. View institutional ownership trends. How do I buy shares of Boston Scientific? Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Boston Scientific own? Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Intel (INTC), Micron Technology (MU), Tesla (TSLA), Salesforce (CRM) and Visa (V). Company Calendar Last Earnings7/29/2026Today10/26/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, BSX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:BSX CIK885725 Webwww.bostonscientific.com Phone(508) 683-4000Fax508-683-5675Employees59,000Year Founded1979Price Target and Rating Average Price Target for Boston Scientific$68.07 High Price Target$124.00 Low Price Target$48.00 Potential Upside/Downside+50.0%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage31 Analysts Profitability EPS (Trailing Twelve Months)$2.47 Trailing P/E Ratio18.34 Forward P/E Ratio14.00 P/E Growth1.1Net Income$2.90 billion Net Margins17.50% Pretax Margin18.39% Return on Equity19.28% Return on Assets10.89% Debt Debt-to-Equity Ratio0.43 Current Ratio1.24 Quick Ratio0.74 Sales & Book Value Annual Sales$20.07 billion Price / Sales3.28 Cash Flow$4.01 per share Price / Cash Flow11.32 Book Value$16.49 per share Price / Book2.75Miscellaneous Outstanding Shares1,449,230,000Free Float1,444,303,000Market Cap$65.75 billion OptionableOptionable Beta0.58 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:BSX) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boston Scientific Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Boston Scientific With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
